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MUTASI PADA GEN FLT3, NPM1, DNMT3a DAN NRAS DALAM LEUKEMIA 
MIELOID AKUT DI HUSM 
ABSTRAK 
Leukemia mieloid akut (AML) adalah sejenis penyakit yang jarang berlaku namun ia di 
antara penyakit yang paling kerap terjadi dalam kumpulan penyakit malignan darah dan 
selalu dikaitkan dengan kematian dalam kalangan orang dewasa. Mutasi pada gen FMS-
tirosina kinase 3 duplikasi dalaman secara rawak (FLT3-ITD) dan nukleofosmin 1 
(NPM1) merupakan mutasi genetik yang kerap berlaku dalam kalangan orang dewasa 
yang menghidapi AML dan masing-masing dikaitkan sebagai prognosis buruk dan 
prognosis baik. Data insiden mutasi bagi gen-gen mutasi yang lazimnya terlibat dalam 
kalangan pesakit AML dewasa masih belum diterbitkan. Dengan itu, kajian ini 
dijalankan adalah untuk menentukan frekuensi bagi gen FLT3-ITD, FLT3-TKD, NPM1, 
DNMT3a dan NRAS, jenis mutasi pada gen-gen tersebut, median kelangsungan hidup 
pesakit bagi kumpulan FLT3-ITD
+
/FLT3-ITD
-
 dan NPM1
+
/NPM1
- 
dalam masa 2 tahun, 
dan perhubungan antara parameter klinikal dengan mutasi gen  FLT3-ITD dan NPM1 
dalam kalangan pesakit AML dewasa di Malaysia. Dalam kajian ini, DNA daripada 54 
pesakit dewasa AML yang baru didiagnosis diambil daripada Hospital Universiti Sains 
Malaysia di Kelantan. Kaedah PCR-CSGE telah digunakan untuk penyaringan mutasi 
pada gen FLT3-ITD dan NPM1 dalam kalangan pesakit AML. Frekuensi mutasi bagi 
gen FLT3-ITD dan NPM1 masing-masing adalah sebanyak 11% dan 13% yang mana 
frekuensinya adalah kurang berbanding data-data yang telah diterbitkan. Analisis 
jujukan menunjukkan kesemua mutasi pada gen FLT3-ITD dan NPM1 adalah unik 
xviii 
 
dalam setiap kes. Berdasarkan analisis tersebut, dua jenis mutasi yang dikenalpasti bagi 
gen FLT3 ekson 14 adalah ITD (sebanyak enam kes) dan bukan ITD (sebanyak satu 
kes). Kedua-dua jenis mutasi ini akan menggangu fungsi „juxtamembrane‟ pada FLT3, 
dengan itu mengakibatkan pengaktifan isyarat pertumbuhan secara terus-menerus. 
Menariknya, satu penemuan baru dikenalpasti dalam mutasi gen NPM1. Walaupun 
mutasi tersebut dijumpai di kawasan domain terminal C, mutasi tersebut tidak 
mengganggu  motif NoLs pada protein NPM. Mutasi gen FLT3-ITD berkaitan secara 
signifikan dengan kehadiran peratusan blast yang tinggi (nilai p = 0.008) dan kiraan sel 
darah putih yang lebih tinggi (nilai p = 0.023) berbanding gen FLT3 yang normal. 
Manakala mutasi pada gen NPM1 pula dikaitkan secara signifikan lebih tinggi dalam 
kalangan wanita berbanding lelaki (nilai p = 0.038). Tiada sebarang mutasi dikesan pada 
gen FLT3-TKD, DNMT3a, dan NRAS. Analisis kelangsungan hidup selama 2 tahun 
pesakit menunjukkan tiada perbezaan secara signifikan bagi keseluruhan kelangsungan 
hidup (OS) dalam kedua-dua kumpulan FLT3-ITD
+
/FLT3-ITD
-
 (nilai p = 0.660) dan 
NPM1
+
/NPM1
- 
(nilai p = 0.714). Walaupun OS dalam kumpulan FLT3-ITD
+
/FLT3-ITD
-
 
tidak menunjukkan perbezaan secara signifikan, median OS bagi pesakit AML yang 
mempunyai FLT3-ITD adalah lebih pendek berbanding pesakit yang mempunyai FLT3 
yang normal (masing-masing 9 dan 52 minggu). Frekuensi bagi mutasi pada gen FLT3-
ITD dan NPM1 adalah lebih tinggi dalam kalangan pesakit AML di Malaysia 
berbanding mutasi pada gen lain iaitu FLT3-TKD, DNMT3a, dan NRAS. 
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FLT3, NPM1, DNMT3a AND NRAS GENES MUTATION IN ACUTE MYELOID 
LEUKAEMIA IN HUSM 
ABSTRACT 
Acute myeloid leukaemia (AML) is a rare but the most common occurrence among 
hematologic malignancy and associated with the greatest mortality in adults. FMS-like 
tyrosine kinase 3-internal tandem duplication (FLT3-ITD) and nucleophosmin 1 (NPM1) 
mutations are the most common genes mutation found in adult AML and have been 
associated with poor and good prognosis, respectively. Published data on the prevalence 
of FLT3-ITD and NPM1 mutations of AML adult patients in Malaysia are not available 
online. Thus, this study was conducted to determine the frequency of FLT3-ITD and 
NPM1 mutation as well as FLT3-TKD, DNMT3a, and NRAS, the types of mutations, 
two-years overall survival/median survival time of FLT3-ITD
+
/FLT3-ITD
-
 and 
NPM1
+
/NPM1
-
 group, and the related clinical data for mutant FLT3-ITD and NPM1 
within the adult Malaysian AML patients. In this study, the genomics DNA from 54 
newly diagnosed adult AML patients were retrieved from Hospital Universiti Sains 
Malaysia, Kelantan. Polymerase chain reaction followed by conformation sensitive gel 
electrophoresis (PCR-CSGE) technique was used to detect gene mutations in AML. The 
frequency of FLT3-ITD and NPM1 mutations were found to be 11% and 13%, 
respectively which were less compared to published data. With respect to sequence 
analysis, all of the mutant FLT3-ITD and NPM1 resulted in variety of amino acid 
sequences in every case. Based on the analysis, two types of mutation have been 
identified in FLT3 exon 14; ITD (six cases) and non-ITD (a single nucleotide deletion) 
xx 
 
(one case). Both kind of mutations would disturb the juxtamembrane domain function in 
FLT3 receptor, thus activate the continuous growth signal. Interestingly, a different 
finding was found in NPM1 mutation. Although the mutation was identified in the 
coding region of C-terminal domain, the mutation does not disturb the NPM nucleolar 
localization signal (NoLs) motif. FLT3-ITD mutation was associated with a significantly 
higher blast percentage (p-value = 0.008) and white blood cell count (p-value = 0.023) 
than the FLT3 wild type. On the other hand, NPM1 mutation were found not to associate 
with blast percentage and white blood cell count but occurred significantly higher in 
female patients (p-value = 0.038). Mutation was not detected in FLT3-TKD, NRAS, and 
DNMT3a genes. Two years overall survival (OS) analysis indicated no significant 
difference in both group, FLT3-ITD+/FLT3-ITD- (p-value = 0.660) and NPM1+/NPM1- 
(p-value = 0.714). Although the OS in FLT3-ITD+/FLT3-ITD- group showed not 
significantly difference, the median OS of AML patients with the FLT3-ITD was shorter 
than those with the wild type (9 versus 52 weeks, respectively). FLT3-ITD and NPM1 
mutations were more prevalent in adult Malaysian AML patients compared to the other 
genes; FLT3-TKD, DNMT3a, and NRAS. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Acute Myeloid Leukaemia 
1.1.1 Definition  
Acute myeloid leukaemia (AML) is heterogenous with respect to clinical manifestation, 
therapy, cytogenetic rearrangement and genetic alteration. AML is defined as a clonal 
proliferation of immature haematopoietic progenitors (myeloblasts) with varying degree 
of myeloid differentiation in the bone marrow, peripheral blood, or extramedullary 
tissues (Vardiman et al., 2009).  
1.1.2 Clinical manifestations and diagnosis 
Clinical manifestations of AML result from proliferation (overproduction) of myeloid 
blast cells and bone marrow failure that leads to decrease in the production of normal 
blood cells; red blood cells (RBCs), other types of white blood cells (WBCs), and 
platelets. As a result of bone marrow failure, AML patients would have anaemia, 
neutropenia and/or thrombocytopenia manifested as fatigue, lethargy, dyspnea, fever, 
weight loss, infection and haemorrhage. AML progresses quickly and typically fatal 
within weeks or months if not treated (Hoffman et al., 2005).  
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The recent definitive diagnosis for AML requires bone marrow aspiration for 
morphologic examination to identify the presence of 20% or more blasts in the marrow. 
In rare cases, for blast count below than 20%, but if cytogenetic aberrations are present 
with a t(8;21)(q22;q22), inv(16)(p13.1q22), t(16;16)(p13.1;q22), or t(15;17)(q22;q12), it 
has to be considered as AML as well (Vardiman et al., 2009). Aside from that, 
cytochemistry, immunology and immunohistochemistry techniques are also used for 
confirmation of AML.  
 
1.1.3 AML classification 
 
Although AML patients share many common clinical manifestations, their leukaemic 
cell morphology, cytogenetics and molecular genetics are obviously heterogenous. Two 
systems have been commonly used to classify AML, the French-American-British 
(FAB) classification and the World Health Organization (WHO) classification. 
 
The older FAB classification divided AML into eight subtypes, M0 through M7, based 
on the type of cell from which the leukaemia developed and its degree of maturity 
(Table 1.1). This classification was based primarily on leukemic cell morphology and 
cytochemical stains (Lowenberg et al., 1999). 
 
The WHO classification of AML is a newer system that incorporates and relates 
morphology, cytogenetic, molecular genetic and immunologic marker (Table 1.2). Using 
WHO criteria, the diagnosis of AML is defined as at least 20% of blasts in the bone 
marrow (BM) required. However, it is not applicable if one of the chromosome 
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abnormalities such as t(8;21)(q22;q22), inv(16)(p13.1q22), or (15;17)(q22;q12) in acute 
pro-myelocytic leukemia (APML) is detected. The presence of these genetic 
abnormalities is sufficient for the diagnosis of AML without blast percentage (Vardiman 
et al., 2009). The WHO classification of AML is more universally applicable and 
prognostically valid.  
 
Although WHO classification is more detailed and perhaps more useful today, the FAB 
classification system is still used in Malaysia. FAB classification can be achieved faster 
and easier as it is only based on morphological examination and cytochemical stains. 
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Table 1.1: FAB classification system of AML (Lowenberg et al., 1999). 
FAB subtype  Common name  
M0  Acute myeloblastic leukaemia with minimal maturation 
M1  Acute myeloblastic leukaemia without maturation 
M2  Acute myeloblastic leukaemia with maturation  
M3  Acute promyelocytic leukaemia (APML)  
M4  
M4Eo 
Acute myelomonocytic leukaemia  
Acute myelomonocytic leukaemia with abnormal eosinophils 
M5  Acute monocytic leukaemia  
M6  Acute erythroid leukaemia  
M7  Acute megakaryoblastic leukaemia  
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Table 1.2: WHO classification system of AML (Vardiman et al., 2009). 
1. AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
AML with mutated NPM1 
AML with mutated CEBPA 
2. AML with myelodysplasia-related changes 
3. Therapy – related myeloid neoplasms (MRC) 
4. AML, not otherwise specified (NOS) 
AML with minimal differentiation  
AML without maturation 
AML with maturation  
Acute myelomonocytic leukaemia 
Acute monoblastic / monocytic leukaemia  
Acute erythroid leukaemia 
         Pure erythroid leukaemia 
         Erythroleukemia, eryhthroid / myeloid 
Acute megakaryoblastic leukaemia  
Acute basophilic leukaemia  
Acute panmyelosis with myelofibrosis 
5. Myeloid sarcoma 
6. Myeloid proliferations related to Down syndrome 
7. Transient abnormal myelopoiesis 
8. Blastic plasmacytoid dendritic cell neoplasm 
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1.1.4 Epidemiology of AML in Malaysia 
The incidence of all leukaemia in the Asian population (7.5 per 100 000 population) is 
lower than that of the White population (13.5 per 100 000 population) (Howlader et al., 
2014). In Malaysia leukaemia was the seventh most common cancer in females and 
fourth in males, with only 2.8 per 100,000 populations (Lim and Halimah, 2004). AML 
is a rare but it is the most common type of leukaemia in adults, and its incidence 
increases with age. The age of Malaysian AML at presentation ranged from four month 
to 81 years with median age of 39 years (Meng et al., 2013). Chromosome aberrations 
were detected in 30% Malaysian AML and the most common chromosome 
abnormalities are t(8;21), trisomy 8, and t(15;17) (Meng et al., 2013).  
 
 
1.2 Genetic pathogenesis in AML 
 
The heterogeneity of AML results from a complex network of chromosome aberrations 
and genetic mutations. Chromosome aberrations, revealed by GTG-banding (G bands by 
Trypsin using Giemsa) are found in 30-50% of AML patients. Genetic mutations occur 
both in cytogenetically normal AML (CN-AML) and in cytogenetically abnormal AML 
(CA-AML) patients (Grimwade and Hills, 2009). Lately, the genetic mutations are 
increasingly being recognized as important diagnostic and prognostic markers in AML. 
In parallel to this important insight, researchers nowadays are trying to develop targeted 
treatments based on interference with molecular genetics as well as epigenetic 
mechanisms. 
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1.2.1 Model of leukaemogenesis 
Many of the mutations identified in AML when existing alone do not lead to 
leukaemogenesis. This is because at least two different types of mutations are required 
for the development of leukaemia. For many years back, the “two-hit” model of 
hypothesis by Gilliland (2001) was accepted as model of leukaemogenesis which 
suggested that development of AML required two different types of genetic mutations, 
class I (proliferative mutation) and class II (blocking mutation) .  
However recently, scientists discovered the presence of a new class of mutation (class 
III) involving epigenetic modifications to the AML genome would also contribute 
towards leukaemogenesis of AML and they cannot be categorized in class I or class II 
mutations (Figure 1.2). Epigenetics is defined as the study of heritable changes in gene 
expression that are not due to modifications in the DNA sequence. Class III mutations 
that confer epigenetic regulation includes genes which encode transcription like 
DNMT3a, IDH1, IDH2 and TET2 (Galm et al., 2006; Figueroa et al., 2009; Jiang et al., 
2009; Barrero et al., 2012). 
Class I mutations confer proliferation and survival advantage. They involve gene coding 
for receptor and non-receptor protein tyrosine kinase like FLT3 and KIT as well as for 
proteins of GTPase activity such as NRAS, which affect proliferative signaling pathways, 
leading abnormal growth of leukemic cells (Kelly and Gilliland, 2002). 
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Class II mutations lead to arrest differentiation of myeloid progenitor cells by affecting 
genes of transcription factors. Genes coding for transcription factors become disrupted 
by their fusion, as a result of chromosome changes (AML1-ETO and PML-RARα), or 
by point mutation (NPM1 and CEBPA). This class of mutation occurs during early 
leukaemogenesis and is stable throughout the disease course. These  mutations have 
been considered as initiating mutations (Kelly and Gilliland, 2002).  
If mutations of class I (excessive myeloproliferation) or class II (differentiation arrest) of 
hematopoietic progenitors occur on its own, it results in the development of 
myeloproliferative syndrome (MPD) or myelodysplastic syndrome (MDS), respectively. 
When these two kinds of mutations occuring sequentially in a single cell, these two-hit 
lead to a fully penetrating AML (Figure 1.1) (Kelly and Gilliland, 2002).  
AML with multilineage dysplasia was introduced in the WHO classification 2001 to 
enclose cases of AML characterized by myelodysplastic syndrome–like features. The 
WHO classification 2008 revised this group into a new category, AML with 
myelodysplasia-related changes (AML-MRC). The category now includes patients with 
at least 20% blasts in peripheral blood or bone marrow and any of the following: (1) 
AML arising from a previous MDS or mixed MDS/myeloproliferative neoplasm, (2) 
AML with a specific MDS-associated cytogenetic abnormality and/or (3) AML with 
multilineage dysplasia (Vardiman et al., 2009; Vardiman and Reichard, 2015).  
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Figure 1.1: “Two-hit” model of leukemogenesis. 
 
 
Figure 1.2: Venn diagram including a new class model of leukemogenesis. 
AML 
AML AML 
AML 
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1.3 Molecularly Targeted Therapies 
 
For over past 40 years, the induction treatment for AML has not changed. The standard 
induction chemotherapy for AML patients remains cytarabine and anthracycline 
combination, also known as 7+3 treatment. This treatment has been troubled by low 
survival rates (10% for 5 years) and deaths due to toxicity. For these reasons, the ability 
to identify specific patients who may get benefit from molecularly targeted therapies 
would give a great promise for AML to improve remission and cure rate. By screening 
for the presence of genetic mutations that are targeted by specific drugs, specific therapy 
would be given based on genetic abnormalities characteristic of the individual patient‟s.  
 
The first targeted therapy in AML was the use of all–trans-retinoic acid (ATRA) for 
acute promyelocytic leukemia (APML/AML-M3) patients. This treatment specifically 
blocks PML-RARA fusion protein function and it appears curable in more than 70% of 
APML patients (Quignon et al., 1997).  
 
A number of new targeted molecular therapies are still under study and clinical trials. 
FLT3 gene mutations is a potentially attractive marker towards molecularly targeted 
therapy in AML as they constitute 1/3 mutations in AML. Nowadays, researchers have 
explored in clinical trials of tyrosine kinase inhibitor (TKI) drugs, including lestaurtinib, 
sorafenib, sunitinib and midostaurin, which were shown to have in-vitro activity against 
FLT3 mutants. During therapy with FLT3 TKIs, the induction of acquired resistance has 
emerged as a clinical problem. Thus, the current focus in clinical research is to find out 
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the optimization of the targeted therapy and the potential treatment options to overcome 
resistance in this situation. 
 
On the other hand, NPM1 mutations which account in 50-60% of CN-AML show a great 
promise for minimal residual disease, as it is stable and persists at relapse (Mrozek et al., 
2007). It appears that NPM1 mutations will become important markers for disease 
monitoring in patients with CN-AML.  
The advent of these molecular agents provides us with a new approach toward AML 
treatment and monitoring. 
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1.4 Rationale of the study 
Cytogenetic alterations have been recognized as the strongest predictive factor for AML 
patients‟ response to therapy and survival for a long time. The lack of chromosome 
aberration in cytogenetically normal AML has proved challenging for the management 
of this clinically heterogeneous disease. However in recent years, several molecular 
markers in AML were discovered within a growing list of genes and allowed more 
precise prognostic predictions and therapeutic decisions. FLT3 (exon 14-15 and 20) and 
NPM1 (exon 12) genes have been chosen in this study because they are the two most 
extensively studied genes for their significant role in prognostic predictions of AML and 
they are the most commonly identified in AML throughout the world. Besides that, we 
also interested to look at the frequency and types of mutation in DNMT3a (exon 23) and 
NRAS (exon 1 and 2) genes.  Unfortunately, we have limited information regarding the 
alteration of these genes in Malaysian AML patients, and also the correlation between 
these genes alteration status and the important clinical parameters associated with AML 
prognosis and treatment. Concerned with that, this study aimed to explore these genetic 
mutations in Malaysian AML cases particularly in the North Eastern State of the 
Peninsular Malaysia and it is truly hoped that the results obtained from this study would 
give us better understanding towards the molecular pathogenesis of AML in Malaysia; 
also would lead to improve diagnostic strategy as well as treatment outcome among 
Malaysian AML population. 
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1.5 Target Genes  
1.5.1 FLT3 gene 
The FLT3 (FMS-like tyrosine kinase receptor III) gene is mapped to chromosome 13q12 
in humans and contains 24 exons. It encodes for the FLT3 receptor protein that belongs 
to class III receptor tyrosine kinase (RTKIII) and composed of 993 amino acids (Zuo et 
al., 2009). The FLT3 receptor is a membrane-bound RTK, which plays a crucial role in 
proliferation, differentiation and apoptosis of normal haematopoietic cells. It comprises 
five immunoglobulin-like domains (Ig-like) in the extracellular ligand binding region, a 
transmembrane domain (TM), a juxtamembrane domain (JM), two intracellular kinase 
domains (TKD1 and TKD2) divided by a kinase insert domain (KI), and a C-terminal 
domain (Figure 1.3) (Abu-Duhier et al., 2001a). 
In normal haematopoietic cells, activation of FLT3 receptor is ligand-dependent. Figure 
1.4 represents FLT3 receptor signaling in normal haematopoietic cell. In the absence of 
ligand, FLT3 receptor is an inactive conformation. Ligand binding to FLT3 receptor 
leads to dimerization on the cell membrane and conformational change of the receptor as 
well as rapid phosphorylation of tyrosine residues on the FLT3 receptor. This in-turn 
activates RAS and PI3K pathways. The activated FLT3 receptor interacts with growth 
factor-bound protein 2 (GRB2) through SHC and activates GRB2 which binds Son of 
Sevenless homolog 1 (SOS). The GRB2-SOS complex is recruited to the membrane 
associated RAS. This activates the MAPK pathway which includes RAF, MEK and 
ERK proteins. Ligand-stimulation of FLT3 activates the GRB2 associated protein 1/2 
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(GAB1/2), and also activates the PI3K-AKT pathway. Phosphorylated ERK and AKT 
result in activation of transcription factors involved in cell proliferation and anti-
apoptosis, respectively. Mutation in the structure FLT3 receptor will lead to a 
continuous growth signal and promote leukaemogenesis (Kiyoi et al., 2002; Stirewalt 
and Radich, 2003). 
 
 
 
 
Figure 1.3: Structure of FLT3 and commonly occurring mutation sites in FLT3. 
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Figure 1.4: FLT3 receptor signaling in normal hematopoietic cell. 
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Mutation in the FLT3 accounts for 25% of all AML cases. They fall into two main 
categories of mutations; internal tandem duplications (FLT3-ITD) in JM and point 
mutations in TKD (FLT3-TKD) (Kiyoi et al., 2002; Meshinchi et al., 2008). FLT3-ITD 
is also known as FLT3 length mutation (FLT3-LM). The length of the ITD varies from 
3-400bp nucleotides (Stirewalt and Radich, 2003). FLT3-ITD accounted in 25% for 
adult (Frohling et al., 2002; Schnittger et al., 2002; Thiede et al., 2002) and 15 % for 
pediatric (Meshinchi et al., 2008). Another most common type of FLT3 mutation is a 
point mutation at codon D835 (aspartate) or I836 (isoleucine) in exon 20 within the 
activation loop of TKD. FLT3-TKD usually is less frequently seen in AML and they 
account for 5% of adult and 3% of peadiatric AML (Abu-Duhier et al., 2001b; 
Yamamoto et al., 2001). Both FLT3-ITD and FLT3-TKD result in ligand independent 
activation and leads to continuous activation of FLT3 receptor (Betz and Hess, 2010; 
Gulley et al., 2010).  
 
FLT3-ITD in AML patients confer poor prognosis which relates to high percentage of 
blast cells, increased risk of relapse from complete remission, and reduced survival 
(Kottaridis et al., 2001; Frohling et al., 2002; Small, 2006; Feng et al., 2012). However, 
the prognosis of FLT3-TKD in AML is still unclear (Whitman et al., 2010; Smith et al., 
2011). The high incidence of FLT3 mutations as well as the poor prognosis status in 
AML eventually stimulated the development of specific treatment for FLT3 aberration. 
 
 
17 
 
1.5.2 NPM1 gene  
The nucleophosmin 1 (NPM1) gene is located on chromosome 5q35 in humans and 
contains 12 exons. It encodes for the nucleophosmin (NPM) proteins which contains 294 
amino acids. The NPM is a multifuntional nucleocytoplasmic shuttling protein localized 
mainly in the granular regions of the nucleolus (Cordell et al., 1999). It has several 
functions which are transporting ribosome components to the cytoplasm for ribosome 
biogenesis (Olson et al., 1986), controlling centrosome duplication during cell division 
(Okuda et al., 2000), and interacting with tumor-suppressors gene (p53 and p19Arf) for 
controlling cell proliferation and apoptosis (Colombo et al., 2002). 
 
Mutations in NPM1 gene are documented in 26-30% of whole adult AML cases (Falini 
et al., 2005; Roti et al., 2006; Boonthimat et al., 2008) and 40-60% of adult CN-AML 
(Mrozek et al., 2007). Their incidences are lower among peadiatric AML (7.5-8%) 
(Bacher et al., 2010; Braoudaki et al., 2010). These mutations are restricted to exon 12 
which encodes for the C-terminus of NPM protein and generally heterozygous. Various 
NPM1 gene mutations were reported in AML at nucleotide positions 956 through 971 
(Chen et al., 2006; Boonthimat et al., 2008). All these mutations are either insertions or 
insertions/deletions producing the frameshift mutation in the C-terminus region of the 
NPM1 gene and these mutations arrest the protein production in the cytoplasm (Mardis 
et al., 2009). 
  
More than 40 different mutations have been identified in exon 12 of the NPM1 gene. 
The most common type of mutations in NPM1 is a duplication of a TCTG between 
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position 956 and 959 and its accounts for 75% of the cases.  Figure 1.5 represents the 
NPM1 mutations type A in C-terminal domain (Grisendi and Pandolfi, 2005).  
 
Figure 1.5: Diagram of the NPM1 mutation type A in exon 12. 
 
 
 
NPM1 mutations are related with an increased in WBCs count (Suzuki et al., 2005a; 
Yan et al., 2007; Boonthimat, 2008), female (Dohner et al., 2005; Schnittger et al., 
2005; Thiede et al., 2006; Gale et al., 2008) and M4/M5 FAB subtypes (Kassem et al., 
2011). NPM1 mutations generally coexist with FLT3-ITD (Dohner et al., 2005; Falini et 
al., 2005; Schnittger et al., 2005; Suzuki et al., 2005a; Verhaak et al., 2005). Only 
NPM1
+
/FLT3-ITD
-
 compilation is recognized as favorable prognostic factor, especially 
in patients aged more than 70 years. AML with NPM1
-
/FLT3-ITD
+
 is related with poor 
prognosis, while AML with NPM1
+
/FLT3-ITD
+
 and NPM1
-
/FLT3-ITD
-
 is associated 
with intermediate prognosis (Thiede et al., 2006; Bacher et al., 2010; Becker et al., 
2010).  
 
NPM1 functions are based on its nucleocytoplasmic shuttling process which is 
controlled by three important domains such as nuclear export signal (NES), nuclear 
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localization signal (NLS) and nucleoli localization signal (NoLS) (Figure 1.6). The NES 
is crucial for transportation of NPM protein from nucleoplasm into cytoplasm. The NLS 
and NoLS are crucial for localization of the NPM protein in nucleoplasm and nucleolus 
(Chen et al., 2006; Falini et al., 2007). 
 
All NPM1 mutations have in a distinct sequence in the NPM protein at the C-terminal 
domain. All of them show loss of at least one of the tryptophan residues (W) at amino 
acid positions 288 and 290 at the C-terminal domain, which lead the frameshift 
mutations and create the common last 5 amino acid residues of VSLRK. The C-terminal 
tryptophans 288 and 290 are essentials for NoLS which is responsible for NPM 
nucleolar localization. The aberration disrupts the NoLS and also brings about an 
additional leucine-rich NES motif at the C-terminal. Both of them play crucial role in 
disrupting the normal nucleocytoplasmic transportation of the NPM protein and creating 
the abnormal cytoplasmic accumulation of the mutant NPM proteins (Figure 1.7) (Chen 
et al., 2006; Falini et al., 2007). 
 
Falini et al. (2007) reported that cytoplasmic accumulation of the mutant NPM protein is 
NES dependent and normal NPM protein contains only one NES domain at amino acid 
position 92-104 (Figure 1.6) (Falini et al., 2006). It binds to the chromosomal region 
maintenance 1 (CRM1) export receptor and facilitates the downstream nuclear export of 
the normal NPM protein for normal functions. The mutant NPM protein however 
contains an extra creation of NES motif at C-terminal domain in which might reinforces 
the accessibility of the NPM mutants towards CRM1 receptor. It would leads to more 
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efficient nuclear export activity than the nuclear import activity and result in the 
uncontrolled cytoplasmic accumulation of NPM protein (Falini et al., 2007). 
 
 
Figure 1.6: Diagram of NPM1 gene, mutant NPM protein and normal NPM protein 
(Leung, 2010). 
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Figure 1.7: Accumulation of mutant NPM proteins in cytoplasm (Leung, 2010).  
1: Dislocation of the mutant NPM proteins from the nucleolus to the nucleoplasm due to 
disruption of the NoLS. 2: Dislocation of the mutant NPM proteins from the 
nucleoplasm to the cytoplasm due to the addition of NES in the C-terminal mutant NPM 
proteins. 
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1.5.3 DNMT3a gene 
DNMT3a (DNA methyl transferase 3α) gene has 23 exons and maps to chromosome 
2p23 in humans. DNMT3a gene encodes a DNA methyltransferase enzyme that is 
actively involved in epigenetic regulation. The DNMT3a enzyme contains three main 
domains stucture, a proline-tryptophan-tryptophan-proline (PWWP) domain, an ATRX, 
DNMT3 and DNMT3L-type finger (ADD) domain, and the methyltransferase (Mtase) 
domain (Figure 1.8)(Weisenberger et al., 2004). This enzyme localizes in the nucleus 
and uses S-adenosyl methionine (SAM) as the methyl group donor being transferred to 
the carbon 5 (C5) position of the cytosine ring in CpG dinucleotide in DNA (Figure 1.9). 
It is responsible for de novo methylation during mammalian development (Brenner and 
Fuks, 2006).  
DNA methylation occurs mainly in the cytosine residues at the C5 positions of CpG di 
nucleotides and is important in regulating gene expression (Chen and Li, 2006). 
Aberrant DNA methylation plays a significant role in the pathogenesis of AML 
(Rosenbauer and Tenen, 2007).  
DNMT3a gene mutations in AML accounted for 7-30% and were related to CN-AML, 
older age, M4/M5 FAB subtypes and poor prognosis (Ley et al., 2010; Thol et al., 2011; 
Hou et al., 2012). Ho et al. (2011) demonstrated that frequency of DNMT3a mutations 
was rare in peadiatric AML. The most frequently mutated site in DNMT3a is Aginine 
882 (R882) residue located in the catalytic domain which led to reduced DNA 
methylation (Ley et al., 2010; Thol et al., 2011). 
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Figure 1.8: Structure of DNMT3a. 
 
 
 
 
Figure 1.9: Methylation of cytosine catalyzed by DNMT3a (Brenner and Fuks, 2006). 
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1.5.4 RAS gene 
The RAS proteins are a family of guanine nucleotide-binding proteins which has 
GTP/GDP binding and GTPase activity. They play important roles in regulatory 
processes including proliferation, differentiation as well as apoptosis (Stirewalt et al., 
2001).  
 
Figure 1.10: RAS signaling pathway. 
 
